A heart transplant is an operation in which the diseased heart in a person is replaced with a healthy heart from a deceased donor. Ninety percent of heart transplants are performed on patients with end-stage heart failure.
Heart failure is a condition in which the heart is damaged or weakened and can't pump enough blood to meet the body's needs. "End-stage" means the condition has become so severe that all treatments, other than heart transplant, have failed.
In March 2016, the Organ Procurement and Transplantation Network revised its criteria for prioritizing children awaiting heart transplantation in the U.S. with the intention of reducing the number of deaths on the waitlist, but a new study suggests unintended consequences.
The confluence of two major health crises—the opioid epidemic and organ shortage—has moved surgeons to consider transplanting organs deemed as less than "perfect" in an effort to expand the donor pool and save more lives, according to research published online today in The Annals of Thoracic Surgery, published by Elsevier.
In a major medical breakthrough, Tel Aviv University researchers have "printed" the world's first 3D vascularised engineered heart using a patient's own cells and biological materials.
Novel studies from around the world showing cutting-edge clinical use of cardiovascular magnetic resonance will be presented at EuroCMR 2019, a meeting of the European Association of Cardiovascular Imaging, a branch of the European Society of Cardiology.
Infectious diseases experts and transplant physicians and surgeons at Brigham and Women's Hospital have blocked the transmission of hepatitis C from infected organ donors to recipients in need of hearts or lungs.
A groundbreaking piece of medical technology was revealed to the public today at the National Research Center for Cardiac Surgery in Astana, Kazakhstan. At a press conference held at the Center, top heart failure experts from around the world announced the successful implantation of FIVAD into a human.
In a study published in iScience, Professor Akiyoshi Fukamizu of the Life Science Center for Survival Dynamics, Tsukuba Advanced Research Alliance (University of Tsukuba, JAPAN) and the research group reported a new work on discovery of the important role of PRMT1 in dilated cardiomyopathy.
Experts at the Vanderbilt Heart and Vascular Institute are forging new ground in the development of a first-of-its-kind program aimed at adults with congenital heart disease.
Experts from the world's major heart surgery organizations-including The Society of Thoracic Surgeons, the American Association for Thoracic Surgery, the Asian Society for Cardiovascular and Thoracic Surgery, and the European Association for Cardio-Thoracic Surgery-are calling for urgent action to develop and implement effective strategies for treating rheumatic heart disease, which affects 33 million people and kills 320,000 annually.
A Smidt Heart Institute patient is the first in the country to receive a new device to fix a leaky heart valve.
The new journal Cardiovascular Innovations and Applications has just published the first issue of Volume 3. This is a Special Issue on Adult Congenital Heart Disease with Guest Editor Diego Moguillansky of the University of Florida Medical School.
The University of Minnesota is the first institution in the state to participate in the phase III clinical trial for CardiAmp Therapy. Previous clinical studies of this therapy have been promising and have shown improvements in patients' quality of life and heart function.
Clinical trial planning is underway at MedStar Heart & Vascular Institute to determine whether a novel stem cell therapy will improve heart function for patients with heart failure.
Shortly after receiving final regulatory approval to launch a new lung transplant program, NYU Langone Health surgeons successfully performed the institution's first procedure, giving two new lungs-;and a new lease on life-;to a Brooklyn woman with a complicated form of pulmonary fibrosis.
The Transplant Institute at NYU Langone Health has launched a new heart transplant program-;the first new program of its kind in New York State in more than 15 years.
A diabetes drug currently undergoing development could be repurposed to help end transplant rejection, without the side-effects of current immunosuppressive drugs, according to new research by Queen Mary University of London.
Heart failure (HF) affects approximately 5.7 million adults in the United States according to the Centers for Disease Control and Prevention. If not properly managed, HF can lead to frequent hospitalizations.
Scientists, nephrologists and cardiac surgeons from The Feinstein Institute for Medical Research and Northwell Health's Department of Internal Medicine, Cardiology and Cardio-Thoracic Surgery examined the impact of a popular pre-heart transplant therapy on the kidney in a study published today by The Clinical Journal of the American Society of Nephrology.
A new study published in the American Heart Association Journal Circulation Research suggests that stem cells derived from umbilical cord show promise in treating heart failure.
A technique borrowed from neuroscience to see through brain tissue is helping scientists to see the fine structure of the heart.